Eli Lilly Issues Voluntary Licenses for Baricitinib to Three Indian Drug Companies  

shot by IP News Shots / 10:27 am on 12 May, 2021

Eli Lilly and Company has issued non-exclusive voluntary licenses for its drug Baricitinib, which is used in the treatment of COVID-19, to three Indian pharma companies. The licensing agreement is signed by Eli Lilly with Cipla Limited, Sun Pharmaceutical Industries Ltd. and Lupin Limited. Interestingly, Natco Pharma Limited had filed for a compulsory license (CL) for Baricitinib with the Indian Patent Office earlier and has already begun manufacturing the drug even as the CL proceedings are underway.

Read More at: https://www.business-standard.com/article/companies/eli-lilly-signs-licensing-pact-with-cipla-sun-lupin-for-covid-19-drug-121051100039_1.html

Industry: Pharmaceuticals | Type of IP: Deals - Licensing